GlassScriptPhysician profile
Shelli M Adam
NPI 1235262866
$8,408.75
in general payments reported to CMS, 2019-2025
27 companies · $3,623 in 2025
The $3,623 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $762 · 2023: $771 · 2024: $3,253 · 2025: $3,623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,486 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,485.53 |
| Education | $160.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,612.67 | 2022-2025 | Linzess, Mavyret, Creon |
| Janssen Biotech, INC. | $1,063.62 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Aimmune Therapeutics, INC. | $679.39 | 2024-2025 | Vowst, Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $634.90 | 2022-2025 | Xifaxan, Relistor, Trulance |
| Gilead Sciences, INC. | $480.28 | 2022-2025 | Livdelzi |
| Madrigal Pharmaceuticals | $476.80 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $416.17 | 2024-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $386.66 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $356.70 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $330.43 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $264.07 | 2024-2025 | Iqirvo, Bylvay |
| Pfizer INC. | $246.73 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $226.08 | 2024-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $205.45 | 2022-2024 | |
| Amgen INC. | $191.16 | 2025 | Uplizna |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $184.62 | 2022-2023 | Dupixent |
| Intercept Pharmaceuticals, INC. | $148.99 | 2022-2025 | |
| Celgene Corporation | $99.30 | 2022-2023 | Zeposia |
| Mallinckrodt Hospital Products INC. | $98.66 | 2024-2025 | Terlivaz |
| Vivus LLC | $89.68 | 2022-2025 | Pancreaze |
| Braintree Laboratories, INC. | $44.89 | 2022-2025 | Suflave, Sutab |
| Lucid Diagnostics INC. | $43.75 | 2023 | |
| Redhill Biopharma INC. | $41.08 | 2022 | |
| Novo Nordisk INC | $30.28 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $26.48 | 2023 | Injectafer |
| Organon LLC | $15.69 | 2024 | |
| Nestle Healthcare Nutrition INC. | $14.22 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shelli Adam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.